Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broadly neutralizing antibodies for HIV-1 prevention and therapy
Boris Jülg, Dan H. Barouch
Seminars in Immunology (2021) Vol. 51, pp. 101475-101475
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 369
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Michal Juraska, Hongjun Bai, Allan C. deCamp, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 4
Open Access | Times Cited: 8
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Boris Jülg, Victoria E. Walker-Sperling, Kshitij Wagh, et al.
Nature Medicine (2024)
Open Access | Times Cited: 5
SHIV fights back to evade destruction by eCD4-Ig but not without suffering debilitating wounds
Eric J. Arts
Molecular Therapy (2025)
Closed Access
Broadly neutralizing monoclonal antibodies for HIV prevention
Maurine D. Miner, Lawrence Corey, David C. Montefiori
Journal of the International AIDS Society (2021) Vol. 24, Iss. S7
Open Access | Times Cited: 33
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
Jérémy Dufloo, Cyril Planchais, Stéphane Frémont, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Next-generation bNAbs for HIV-1 cure strategies
Angela I. Schriek, Yoann Aldon, Marit J. van Gils, et al.
Antiviral Research (2023) Vol. 222, pp. 105788-105788
Open Access | Times Cited: 12
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Sharana Mahomed
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 4
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Sharana Mahomed, Nigel Garrett, Edmund V. Capparelli, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 3, pp. 510-520
Open Access | Times Cited: 21
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing
Lauren Walker, Andrea R. Shiakolas, Rohit Venkat, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity
Allison S. Thomas, Yvetane Moreau, Wenqing Jiang, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 10, pp. 100412-100412
Open Access | Times Cited: 20
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
Seemal F. Awan, Myra Happe, Amelia R. Hofstetter, et al.
Current Opinion in HIV and AIDS (2022) Vol. 17, Iss. 4, pp. 247-257
Closed Access | Times Cited: 15
A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin
Eirini Vamva, Stosh Ozog, Daniel P. Leaman, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 28, pp. 366-384
Open Access | Times Cited: 8
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Christopher O. Barnes, Till Schoofs, Priyanthi N.P. Gnanapragasam, et al.
Science Advances (2022) Vol. 8, Iss. 32
Open Access | Times Cited: 12
Vaccinal effect of HIV-1 antibody therapy: dream or reality?
Mar Naranjo‐Gómez, Mireia Pelegrín
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 4, pp. 209-216
Closed Access | Times Cited: 7
Genome edited B cells: a new frontier in immune cell therapies
Geoffrey L. Rogers, Paula M. Cannon
Molecular Therapy (2021) Vol. 29, Iss. 11, pp. 3192-3204
Open Access | Times Cited: 17
Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity
Christina B. Karsten, Falk F. R. Buettner, Samanta Cajic, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 5, pp. e1012190-e1012190
Open Access | Times Cited: 1
Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs
Chuangqi Wang, Timothy E. Schlub, Wen‐Han Yu, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 8, pp. 1342-1350
Open Access | Times Cited: 8
Development of screening assays for use of broadly neutralizing antibodies in people with HIV
Rebecca M. Lynch, Katharine J. Bar
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 4, pp. 171-177
Closed Access | Times Cited: 4
Clinical trials aimed at HIV cure or remission: new pathways and lessons learned
Maya Dyveke Schou, Ole S. Søgaard, Thomas A. Rasmussen
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 11, pp. 1227-1243
Closed Access | Times Cited: 3
Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
Brian D. Williamson, Craig A. Magaret, Shelly Karuna, et al.
iScience (2023) Vol. 26, Iss. 9, pp. 107595-107595
Open Access | Times Cited: 2
Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure
Karunasinee Suphaphiphat, Delphine Desjardins, Valérie Lorin, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 2
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6
Tumelo Moshoette, Maria A. Papathanasopoulos, Mark Andrew Killick
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 4
Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection
Tawanda Mandizvo, Nombali Gumede, Bongiwe Ndlovu, et al.
Journal of Virology (2022) Vol. 96, Iss. 24
Open Access | Times Cited: 4
Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings
Kristin L. Boswell, Timothy A. Watkins, Evan M. Cale, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top